image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 69.21
-1.75 %
$ 1.49 B
Market Cap
-65.38
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ANIP stock under the worst case scenario is HIDDEN Compared to the current market price of 69.2 USD, ANI Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ANIP stock under the base case scenario is HIDDEN Compared to the current market price of 69.2 USD, ANI Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ANIP stock under the best case scenario is HIDDEN Compared to the current market price of 69.2 USD, ANI Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANIP

image
$70.0$70.0$68.0$68.0$66.0$66.0$64.0$64.0$62.0$62.0$60.0$60.0$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
614 M REVENUE
26.20%
584 K OPERATING INCOME
-98.76%
-18.5 M NET INCOME
-98.63%
64 M OPERATING CASH FLOW
-46.19%
-405 M INVESTING CASH FLOW
-2086.37%
265 M FINANCING CASH FLOW
292.87%
191 M REVENUE
28.48%
-4.38 M OPERATING INCOME
78.66%
-10.3 M NET INCOME
54.04%
15.9 M OPERATING CASH FLOW
27.14%
-10.7 M INVESTING CASH FLOW
97.32%
-4.91 M FINANCING CASH FLOW
-1.69%
Balance Sheet ANI Pharmaceuticals, Inc.
image
Current Assets 528 M
Cash & Short-Term Investments 151 M
Receivables 222 M
Other Current Assets 155 M
Non-Current Assets 756 M
Long-Term Investments 0
PP&E 56.9 M
Other Non-Current Assets 699 M
11.78 %17.27 %12.06 %4.43 %54.46 %Total Assets$1.3b
Current Liabilities 194 M
Accounts Payable 45.7 M
Short-Term Debt 9.17 M
Other Current Liabilities 139 M
Non-Current Liabilities 661 M
Long-Term Debt 306 M
Other Non-Current Liabilities 356 M
5.34 %16.24 %35.76 %41.59 %Total Liabilities$855.2m
EFFICIENCY
Earnings Waterfall ANI Pharmaceuticals, Inc.
image
Revenue 614 M
Cost Of Revenue 0
Gross Profit 614 M
Operating Expenses 614 M
Operating Income 584 K
Other Expenses 19.1 M
Net Income -18.5 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)614m0614m(614m)584k(19m)(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
0.10% OPERATING MARGIN
0.10%
-3.01% NET MARGIN
-3.01%
-4.32% ROE
-4.32%
-1.44% ROA
-1.44%
0.04% ROIC
0.04%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ANI Pharmaceuticals, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -18.5 M
Depreciation & Amortization 67.7 M
Capital Expenditures 0
Stock-Based Compensation 29.3 M
Change in Working Capital 0
Others 7.38 M
Free Cash Flow 64 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ANI Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ANIP of $82 , with forecasts ranging from a low of $60 to a high of $94 .
ANIP Lowest Price Target Wall Street Target
60 USD -13.31%
ANIP Average Price Target Wall Street Target
82 USD 18.48%
ANIP Highest Price Target Wall Street Target
94 USD 35.82%
Price
Max Price Target
Min Price Target
Average Price Target
9595909085858080757570706565606055555050Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership ANI Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
642 K USD 3
3-6 MONTHS
2.85 M USD 5
6-9 MONTHS
43.4 K USD 1
9-12 MONTHS
15.2 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
4 Stocks Trading Near 52-Week High With Room to Rise Further Investors target stocks that have been on a bullish run lately. Stocks like ANIP, HRTG, AVA and EXC are seeing price strength and the momentum is likely to continue. zacks.com - 1 week ago
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2 weeks ago
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) ANI (ANIP) could produce exceptional returns because of its solid growth attributes. zacks.com - 3 weeks ago
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 3 weeks ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. zacks.com - 3 weeks ago
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. globenewswire.com - 3 weeks ago
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year. zacks.com - 3 weeks ago
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Expand Energy, Avista & Contango are well-poised to gain. zacks.com - 3 weeks ago
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately. zacks.com - 4 weeks ago
5 Relative Price Strength Stocks to Navigate Today's Market IHS, ANIP, MD, FMS and TREE are five stocks with explosive relative price strength. zacks.com - 1 month ago
5 High Earnings Yield Value Picks to Counter Market Uncertainty Unlock your portfolio value with high earnings yield stocks like ANI Pharma, Insteel, Pitney Bowes, IHS Holding and HighPeak Energy. zacks.com - 1 month ago
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference as follows: globenewswire.com - 1 month ago
8. Profile Summary

ANI Pharmaceuticals, Inc. ANIP

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.49 B
Dividend Yield 0.04%
Description ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Contact 210 Main Street West, Baudette, MN, 56623 https://www.anipharmaceuticals.com
IPO Date May 5, 2000
Employees 897
Officers Ms. Meredith W. Cook J.D. Senior Vice President, General Counsel & Corporate Secretary Mr. Muthusamy Shanmugam MS R.Ph. Head of R&D, Chief Operating Officer of New Jersey Operations & Director Dr. Mary Pao M.D., Ph.D. Chief Medical Officer Mr. Christopher K. Mutz Senior Vice President & Head of Rare Disease Ms. Krista L. Davis Senior Vice President & Chief Human Resources Officer Mr. Stephen P. Carey Senior Vice President of Finance & Chief Financial Officer Mr. Nikhil Lalwani President, Chief Executive Officer & Director Mr. Ori Gutwerg Senior Vice President of Generics Ms. Elizabeth Powell J.D. Chief Compliance Officer & Head of Legal of Rare Disease Mr. Chad Gassert Senior Vice President of Corporate Development & Strategy